All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
A lymphoma working party session took place at the 44th European Society for Blood and Marrow Transplantation (EBMT) annual meeting on 20 March 2018. Abstract WP7-6 won the Jian-jian Luan award for the best abstract in the topic of Lymphoma. The abstract presented by Anne-Claire Mamez, Hôpitaux Universitaires de Genève, Department of Hematology, Geneva on the role of allogeneic stem cell transplant (allo-SCT) use in patients with peripheral T-cell lymphoma (PTCL).
The retrospective analysis assessed PTCL patients who had allo-SCT between 2006 and 2014 using the Francophone Society of bone marrow transplantation and cellular therapy (SFGM)-TC database. Two-hundred and eighty-four patients were included in the study with a median age of 50 years (range, 16–69) were transplanted at a median of 12.6 months after diagnosis.
Patients received transplant as either first-line treatment (29%), after 2 lines (36%) and after ≥3 lines (35%). The speaker noted that 94% of patients had a Karnofsky performance status of above 80%. The donors for allo-SCT were either matched-related (45%), matched-unrelated (36%) or alternative (19%). Conditioning regimens given included: reduced intensity conditioning (RIC) n = 147, myeloablative (MAC) n = 106 and non-myeloablative (NMA) n = 27.
The speaker concluded that according to the study findings at long term follow-up, grade ≥3 GvHD and low Karnofsky scores negatively impacted OS. Additionally, the conditioning regimen did not significantly influence OS.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox